MX2021004883A - Metodos y composiciones para tratar apnea del sue?o. - Google Patents

Metodos y composiciones para tratar apnea del sue?o.

Info

Publication number
MX2021004883A
MX2021004883A MX2021004883A MX2021004883A MX2021004883A MX 2021004883 A MX2021004883 A MX 2021004883A MX 2021004883 A MX2021004883 A MX 2021004883A MX 2021004883 A MX2021004883 A MX 2021004883A MX 2021004883 A MX2021004883 A MX 2021004883A
Authority
MX
Mexico
Prior art keywords
methods
sleep apnea
compositions
treating sleep
hydroxyatomoxetine
Prior art date
Application number
MX2021004883A
Other languages
English (en)
Inventor
Lawrence G Miller
Ronald Farkas
Original Assignee
Apnimed Inc Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed Inc Delaware filed Critical Apnimed Inc Delaware
Publication of MX2021004883A publication Critical patent/MX2021004883A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

En general, la invención hace referencia a composiciones farmacéuticas que comprenden 4-hidroxiatomoxetina usada con un antagonista del receptor muscarínico, y métodos para tratar la apnea del sueño que comprende administrar un antagonista del receptor muscarínico y 4-hidroxiatomoxetina. La 4-hidroxiatomoxetina y el antagonista del receptor muscarínico se colocan juntos en un portador farmacéuticamente aceptable.
MX2021004883A 2018-10-31 2019-07-23 Metodos y composiciones para tratar apnea del sue?o. MX2021004883A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862753420P 2018-10-31 2018-10-31
PCT/US2019/043065 WO2020091862A1 (en) 2018-10-31 2019-07-23 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
MX2021004883A true MX2021004883A (es) 2021-08-05

Family

ID=67539629

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004883A MX2021004883A (es) 2018-10-31 2019-07-23 Metodos y composiciones para tratar apnea del sue?o.

Country Status (9)

Country Link
US (1) US20210401790A1 (es)
EP (1) EP3873454A1 (es)
JP (1) JP2022506113A (es)
KR (1) KR20210084481A (es)
CN (1) CN112930179A (es)
AU (1) AU2019370091A1 (es)
CA (1) CA3117766A1 (es)
MX (1) MX2021004883A (es)
WO (1) WO2020091862A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022294086A1 (en) * 2021-06-17 2024-01-04 Apnimed, Inc. (Delaware) Norepinephrine reuptake inhibitors for treating sleep apnea
WO2023118123A1 (en) * 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combination of an α2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
WO2023118126A1 (en) * 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combination of a task1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
WO2024049885A1 (en) * 2022-09-02 2024-03-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
GEP20227387B (en) * 2017-04-28 2022-06-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
JP2022506113A (ja) 2022-01-17
US20210401790A1 (en) 2021-12-30
WO2020091862A1 (en) 2020-05-07
CN112930179A (zh) 2021-06-08
CA3117766A1 (en) 2020-05-07
KR20210084481A (ko) 2021-07-07
EP3873454A1 (en) 2021-09-08
AU2019370091A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12015501596A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2015002378A (es) Composicion ansiolitica, formulacion y metodo de uso.
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MY196869A (en) Cancer treatment combinations
MX2021002321A (es) Nuevos metodos.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2021001845A (es) Un medicamento combinado que comprende fenilefrina y paracetamol.
EP2566502A4 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
MX2014014813A (es) Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño.
MX2021000312A (es) Composicion farmaceutica que contiene un peptido.
MX2017014725A (es) Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.
MX2015009504A (es) Composicion farmaceutica de desloratadina para ser administrada por via oral, para el tratamiento de enfermedades relacionadas con la histamina.
PH12014501390A1 (en) Novel therapeutic use of p75 receptor antagonists